Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.

The targeting of oncogenic 'driver' kinases with small molecule inhibitors has proven to be a highly effective therapeutic strategy in selected non-small cell lung cancer (NSCLC) patients. However, acquired resistance to targeted therapies invariably arises and is a major limitation to pat...

Full description

Bibliographic Details
Main Authors:	Kurtis D Davies, Sakshi Mahale, David P Astling, Dara L Aisner, Anh T Le, Trista K Hinz, Aria Vaishnavi, Paul A Bunn, Lynn E Heasley, Aik-Choon Tan, D Ross Camidge, Marileila Varella-Garcia, Robert C Doebele
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3862576?pdf=render

Similar Items

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
by: Kathryn E Ware, et al.
Published: (2010-11-01)

A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
by: Natalia J. Gurule, et al.
Published: (2021-05-01)

Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay
by: Varella-Garcia Marileila
Published: (2006-08-01)

Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer
by: Tejas Patil, et al.
Published: (2020-04-01)

Assessing residual leukemia through fluorescence in situ hybridization
by: Marileila Varella-Garcia
Published: (1998-09-01)

A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
by: Jose M. Pacheco, et al.
Published: (2019-03-01)

ALK and ROS1 concurrent with EGFR mutation in patients with lung adenocarcinoma
by: Mao Y, et al.
Published: (2017-07-01)

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
by: Jeet Gandhi, et al.
Published: (2009-01-01)

Biomarkers that currently effect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1 and KRAS
by: Grzegorz Janusz Korpanty, et al.
Published: (2014-08-01)

Lung cancer with concurrent EGFR mutation and ROS1 rearrangement: a case report and review of the literature
by: Zhu YC, et al.
Published: (2016-07-01)

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
by: Jongmin Lee, et al.
Published: (2019-01-01)

Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET
by: Ha-Na Oh, et al.
Published: (2020-02-01)

Synthesis of Triazole-Substituted Quinazoline Hybrids for Anticancer Activity and a Lead Compound as the EGFR Blocker and ROS Inducer Agent
by: Biswadip Banerji, et al.
Published: (2018-11-01)

Next Generation Sequencing Reveals a Synchronous Trilateral Lung Adenocarcinoma Case with Distinct Driver Alterations of EGFR 19 Deletion or EGFR 20 Insertion or EZR-ROS1 Fusion
by: Zhang X, et al.
Published: (2020-12-01)

Microvesicles: ROS scavengers and ROS producers
by: G. Bodega, et al.
Published: (2019-12-01)

ROS and ROS-Mediated Cellular Signaling
by: Jixiang Zhang, et al.
Published: (2016-01-01)

Studies on the adaptors of clathrin-coated vesicles
by: Camidge, David Ross
Published: (1992)

Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
by: Yi Yao, et al.
Published: (2019-02-01)

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
by: Masaya Nishino, et al.
Published: (2021-05-01)

Genomic imbalances in esophageal squamous cell carcinoma identified by molecular cytogenetic techniques
by: Marilanda Ferreira Bellini, et al.
Published: (2010-01-01)

Epidermal Growth Factor (EGF) Augments the Invasive Potential of Human Glioblastoma Multiforme Cells via the Activation of Collaborative EGFR/ROS-Dependent Signaling
by: Maciej Pudełek, et al.
Published: (2020-05-01)

Alterations in genes other than <i>EGFR/ALK/ROS1</i> in non-small cell lung cancer: trials and treatment options
by: Arpita Desai, et al.
Published: (2016-03-01)

Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
by: Xibin Zhuang, et al.
Published: (2019-06-01)

Condensation et évaporation de l'hexane dans les membranes d'alumine poreuse
by: Doebele, Victor
Published: (2019)

Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma
by: Zübeyde Ekin, et al.
Published: (2021-09-01)

ROS mediates EGFR transactivation by c-Src in arsenic trioxide-regulated p21WAF1/CIP1gene expression in human keratinocytes
by: Hong-YuTseng, et al.
Published: (2013)

Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations
by: Richard S.P. Huang, MD, et al.
Published: (2021-02-01)

Chemotherapy combined with Endostar as salvage treatment for EGFR‐tyrosine kinase inhibitor primary resistance in an advanced non‐small cell lung cancer patient with EGFR L858R mutation and ROS1 fusion: A case report
by: Dong Qiu, et al.
Published: (2019-04-01)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
by: Seo Yun Kim, M.D., et al.
Published: (2019-01-01)

EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway
by: Yun Yang, et al.
Published: (2018-01-01)

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
by: Thang Thanh Phan, et al.
Published: (2019-01-01)

Interleukin-1β Induces Tissue Factor Expression in A549 Cells via EGFR-Dependent and -Independent Mechanisms
by: Tobias Mechelke, et al.
Published: (2021-06-01)

Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK, and ROS1 versus next-generation sequencing (NGS) in advanced adenocarcinoma lung cancer patients
by: Luciene Schluckebier, et al.
Published: (2020-09-01)

Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as “ROS1” as it appears?
by: Navneet Singh
Published: (2017-01-01)

Neanderthals in the landscape : the impact of terrain and environmental variability on raw material economy in the Late Middle Palaeolithic of northeast Italy
by: Heasley, Kristen
Published: (2015)

Young people's views concerning their voice in Education, Health and Care planning meetings : a participatory Q-study
by: Heasley, Jonathan
Published: (2017)

THE ROLE OF ROS1 GENE IN DEVELOPMENT OF STROKE
by: D. A. Nikulin, et al.
Published: (2015-10-01)

ROS and the DNA damage response in cancer
by: Upadhyayula Sai Srinivas, et al.
Published: (2019-07-01)

Role of epidermal growth factor receptor inhibitor-induced interferon pathway signaling in the head and neck squamous cell carcinoma therapeutic response
by: Sean P. Korpela, et al.
Published: (2021-01-01)

Oxygen and ROS in Photosynthesis
by: Sergey Khorobrykh, et al.
Published: (2020-01-01)